top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Search

Ovid Therapeutics announces CEO transition effective January 2026

bancheta6
5 days ago
1 min read

New York, November 12, 2025 (Globe Newswire) -- Ovid Therapeutics unveiled a CEO succession plan in which Meg Alexander will become Chief Executive Officer and join the Board on January 1, 2026, while co-founder Dr. Jeremy Levin shifts to Executive Chairman. The announcement accompanied the company’s third-quarter 2025 financial results and updates on its pipeline progress. Alexander, who has played a key role in shaping the company’s strategy and operations since 2021, will work closely with Dr. Levin during the transition to ensure continuity.

Read article here.

Recent Posts

Hippocratic AI closes $126M Series C at $3.5B valuation

Palo Alto, CA, November 3, 2025 (Business Wire) -- Hippocratic AI raised $126 million in a Series C round, bringing its total funding to $404 million and valuing the company at $3.5 billion. The rou

J&J to Acquire Halda Therapeutics for $3.05B

New Haven, CT, November 17, 2025 (Reuters) -- Johnson & Johnson will acquire Halda Therapeutics in a $3.05 billion all-cash deal aimed at accelerating Halda’s RIPTAC™ platform for solid tumors. The

AdvanCell Names Philina Lee as New CEO to Lead U.S. Expansion

Sydney & Boston, November 17, 2025 (Business Wire) -- AdvanCell has appointed biopharma executive Philina Lee, PhD, as its new Chief Executive Officer, effective January 1, 2026. Based in the compan

Life Science Headlines

Hippocratic AI closes $126M Series C at $3.5B valuation

Ovid Therapeutics announces CEO transition effective January 2026

J&J to Acquire Halda Therapeutics for $3.05B

AdvanCell Names Philina Lee as New CEO to Lead U.S. Expansion

Pfizer Finalizes $7B Acquisition of Metsera to Bolster Obesity Pipeline

Azalea Therapeutics launches with $82M to pioneer in vivo precision genomic medicines

BrainScope Appoints Matt Adams as CEO to Drive Next Phase of AI-Powered Brain Health Innovation

Braveheart launches with $185M to advance heart drug rivaling Bristol Myers’ therapy

Recursion Announces CEO Transition to Propel Next Growth Phase

Thermo Fisher Scientific to Acquire Clario Holdings for $8.9B to Deepen Clinical Insights and Accelerate Drug Development

bottom of page